Introduction
============

Calcifying fibrous tumor (CFT) was first described as a 'childhood fibrous tumor with psammoma bodies' by Rosenthal and Abdul-Karim ([@b1-etm-0-0-6892]) in 1988, but later studies demonstrated it may also occur among the adult population ([@b2-etm-0-0-6892],[@b3-etm-0-0-6892]). CFT is a rare but distinctive entity; it is a benign lesion that consists of abundant hyalinized collagen with psammomatous or dystrophic calcifications ([@b4-etm-0-0-6892]). CFTs primarily originate from the soft tissue, e.g. pleura and abdominal viscera; the stomach only rarely participates ([@b5-etm-0-0-6892]). CFT confined to the gastric wall is a rare and benign lesion, which usually presents without any gastrointestinal symptoms and is often detected incidentally ([@b5-etm-0-0-6892]). Gastric CFT is less likely to cause serious complications such as perforation or obstruction. In spite of its benign course and good prognosis, with known histological and immunohistochemical features, the exact pathogenic mechanism of this lesion remains elusive. Gastric CFT should be carefully differentiated from other spindle cell mesenchymal lesions involved in the stomach, such as inflammatory myofibroblastic tumor, sclerosing calcified gastrointestinal stromal tumor, schwannoma and IgG4-related sclerosing disease. Furthermore, given the rarity of gastric CFT (less than 50 cases reported to date), it is important to enhance the understanding of this lesion among clinicians. Therefore, the present study focused on exploring its clinical and pathological features by presenting 9 cases of gastric CFT, and reviewing previous English language articles regarding gastric CFT to determine whether this kind of tumor has a sex predilection. Furthermore, the current study aimed to analyze the possible association between female predominance and expression of G protein-coupled estrogen receptor (GPER).

Subjects and methods
====================

The clinical information, relevant biochemical indicators \[blood routine, tumor markers, C reactive protein, hepatitis B virus and *Helicobacter pylori* (HP)\] and pathological features (gross examination and microscopic findings) of 9 patients with gastric CFT who had been admitted to the Department of Gastroenterology and Gastrointestinal Surgery at the Renmin Hospital of Wuhan University (Wuhan, China) between January 2015 and July 2018 were retrospectively reviewed. The present protocol was approved by the Institutional Review Board of the Renmin Hospital of Wuhan University, and all patient data was handled confidentially. All patients included in the present study provided written informed consent. The tumor slides from the 9 cases were collected from the Department of Pathology of the Renmin Hospital of Wuhan University. In addition, literature databases up to July 2018 were searched, including PubMed ([www.ncbi.nlm.nih.gov/pubmed](www.ncbi.nlm.nih.gov/pubmed)), Embase ([www.embase.com](www.embase.com)), Scopus ([www.scopus.com](www.scopus.com)) and Google Scholar ([scholar.google.com](scholar.google.com)), for previously published English language articles regarding gastric CFT case reports or case series. The search terms were 'calcifying fibrous tumor AND gastric', and 'calcifying fibrous pseudotumor AND gastric'. Two authors reviewed potential studies, and any discrepancies were resolved by a third author.

Tumor specimens resected by endoscopic submucosal dissection (ESD) or gastric wedge excision (GWE) were fixed in 10% formalin solution for 4 h at room temperature and embedded in paraffin using routine methods. Deparaffinized sections with 4 µm thickness were used for staining with hematoxylin and eosin (5 min for hematoxylin and 1 min for eosin). Immunohistochemical techniques were conducted according to the SP method as described previously ([@b6-etm-0-0-6892]). Deparaffinized sections with 4 µm thickness were quenched in 3% H~2~O~2~, then subjected to antigen retrieval in boiling citric acid (pH 6.0) for 15 min and washed with PBS. Following incubation overnight with primary antibodies against GPER (ab39742; 1:200), estrogen receptor (ER; ab17230; 1:200) or vimentin (ab24525; 1:5,000; all from Abcam, Cambridge, UK) at 4°C, the sections were incubated for 15 min at room temperature with horseradish peroxidase-labeled polymer-conjugated secondary antibodies (MaxVision™ kits; Maxim Bio, Fujian, China). The specimens were then incubated for 1 min at room temperature with diaminobenzidine (Maxim Bio). Finally, the sections were counterstained at room temperature with hematoxylin for 30 sec.

Results
=======

### Clinical characteristics of the 9 cases

Six patients (cases 4--9) originally attended the hospital for a check-up for non-specific symptoms, such as belching or a bloated abdomen. Among the 9 cases, there were 6 female patients and 3 male patients (2:1). The age of the patients ranged from 40--71 years, with a mean age of 52.22 years. A total of 6 tumor cases (cases 1, 2, 5, 6, 7 and 8) originated from the gastric body, whereas the remaining 3 originated from the fundus of the stomach (cases 3, 4 and 9; [Table I](#tI-etm-0-0-6892){ref-type="table"}). Cases 1 and 9 were concomitant with reflux esophagitis, case 2 was accompanied with duodenal ulcer, and erosive hemorrhagic gastritis and hypertension were reported in case 3. Furthermore, type 2 diabetes and superficial gastritis were diagnosed in cases 6 and 8, respectively. No patients were reported to suffer from autoimmune disorders. The details of smoking, alcohol consumption and body mass index are listed in [Table I](#tI-etm-0-0-6892){ref-type="table"}.

### Laboratory tests

No abnormalities were evident in routine and tumor marker blood tests \[including carcinoembryonic antigen, α-fetoprotein, carbohydrate antigen (CA)19-9 and CA-125\]. Cases 1 and 2 presented with chronic hepatitis B virus (HBV) infection, and cases 1, 3 and 8 were positive in the ^13^C breath test and diagnosed with HP infection ([Table II](#tII-etm-0-0-6892){ref-type="table"}). Furthermore, C-reactive protein (CRP) levels were slightly elevated in 5 cases (cases 1, 2, 3, 7 and 8).

### Gross examination and microscopic findings

Sections from all 9 cases revealed well-defined lumps; each section contained an isolated nodular lesion covered by intact mucosa. The maximum diameter ranged from 1.3--2.5 cm, with a mean of 1.81 cm. A total of 4 tumors (cases 2, 3, 4 and 8) were located in the lamina propria, with extension to the submucosa, whereas the remaining 5 cases (1, 5, 6, 7 and 9) occurred in the submucosa ([Table I](#tI-etm-0-0-6892){ref-type="table"}).

Microscopically, the common characteristics of the 9 cases included considerable hypocellular sclerosis and wavy storiform coarse collagen infiltrated with scattered or patchy mononuclear inflammatory cells. Six cases (cases 1, 2, 4, 5, 6 and 9) exhibited a predominance of dense hyaline fibrous tissue infiltrated with many inflammatory cells and multifocal dystrophic calcifications. Psammomatous and dystrophic calcifications are indicated in [Fig. 1](#f1-etm-0-0-6892){ref-type="fig"}.

### Immunohistochemical staining

From the immunohistochemical examination of gastric CFT specimens, lesional cells were determined to be positive for vimentin and GPER expression. However, all 9 cases were negative for ER expression ([Fig. 2](#f2-etm-0-0-6892){ref-type="fig"}).

### Treatment and follow-up

A total of 8 patients were treated with ESD; only 1 patient (case 6) underwent partial gastrectomy. Following ESD or surgical treatment, all patients recovered fully. None of the 9 patients available to follow-up (mean follow-up time, 13.11 months; range, 4--25 months) have experienced local recurrence ([Table I](#tI-etm-0-0-6892){ref-type="table"}).

### Literature search

In total, 25 previous studies regarding gastric CFT were identified, including 39 individual cases ([Table III](#tIII-etm-0-0-6892){ref-type="table"}) ([@b7-etm-0-0-6892]--[@b31-etm-0-0-6892]). At present, there are 48 cases of gastric CFT reported in the English language literature, including the 9 cases from the present study. Among the 48 cases of gastric CFT, there were 28 female and 20 male patients, a sex ratio of 1.4:1. The number of female patients was more than twice that of the male patients in the patients \<50 years of age (17 vs. 8), whereas the number was almost equal between women and men ≥50 years of age (11 vs. 12; [Fig. 3](#f3-etm-0-0-6892){ref-type="fig"}). Regarding geographical distribution of the gastric CFT patients, Asia ranked the highest (including 17 patients in China, 4 in Korea, 3 in Japan, 1 in Kuwait, 1 in Turkey and 1 in Pakistan), followed by Europe (7 patients in Germany, and 1 in each of Greece, Slovakia, Switzerland, France and Italy), whereas only 9 cases occurred in North America (8 patients in the USA and 1 in Canada). According to the distribution of these 48 cases, it appears that people from Asia, especially from East Asia, are more likely to suffer from this disease than people from Europe or North America, potentially due to ethnic or regional differences.

Discussion
==========

To the best of our knowledge, the present study reported the largest case series on gastric CFTs to date. Among the 9 gastric CFT patients included in this study, 3 were infected with HP, and 2 with HBV. Due to the extremely low incidence of this type of tumor, there is no previous research considering the association between the occurrence of gastric CFT and HP or HBV. In addition, the distribution of the 48 reported cases indicated that people from East Asia may be more likely to suffer from this disease compared with people from Europe or North America. Whether this is a coincidence requires further exploration.

At present, the etiology and pathogenesis of CFT confined to the gastric wall remain elusive ([@b5-etm-0-0-6892],[@b11-etm-0-0-6892]--[@b14-etm-0-0-6892]). In a previous study, cases of CFT following trauma were reported, and it has been speculated that gastric CFT may represent a localized inflammatory fibrosclerosis in response to tissue injury affecting the stomach ([@b32-etm-0-0-6892]). However, no prior history of any trauma or tissue injuries to the stomach, such as ulcers or perforation, were identified in the present 9 cases. Furthermore, previous studies have indicated that these tumors are true neoplasms, with the potential for non-destructive local recurrence ([@b33-etm-0-0-6892]), rather than a reactive process resulting from abnormal tissue healing ([@b5-etm-0-0-6892],[@b7-etm-0-0-6892]). It has also been suggested that this lesion results from an immunoglobulin (Ig)G4-associated disorder ([@b34-etm-0-0-6892],[@b35-etm-0-0-6892]); gastric CFTs may represent a stage of an IgG4-associated disorder, and steroid therapy should be included in clinical management prior to GWE or ESD ([@b18-etm-0-0-6892]). However, among the present 9 cases, none of the patients presented with autoimmune disorders such as primary biliary cirrhosis, chronic atrophic gastritis, inflammatory bowel disease or IgG4-associated pancreatitis.

The present study demonstrated that gastric CFT may have a female predominance (female:male, 2:1), which is consistent with the previous literature (1.27:1) ([@b5-etm-0-0-6892],[@b13-etm-0-0-6892]). Including the 9 cases in the current study and the 39 from previous studies, the sex ratio is 1.4:1. Following age stratification, a marked difference was identified in the sex ratio of patients above or below age 50. This suggests that this rare tumor is more common in female patients, particularly premenopausal women. Based on the marked difference in sex ratio before and after age 50, it is speculated that estrogen may serve a role in the occurrence and progression of gastric CFT.

As estrogen exerts its effects via binding GPER or ER, the ER and GPER expression status of the patient samples was detected with immunohistochemistry. Immunostaining was performed on samples from 9 cases; cells from the lesions exhibited positive immunoreactivity for GPER, but no immunoreactivity for ER. ER, also known as classical steroid receptor, is a ligand-activated nuclear transcription factor that recognizes cis-acting hormone response elements in the promoters of hormonally regulated genes ([@b36-etm-0-0-6892]). The present results revealed that the ER mediation of the classical genomic signal pathway was not associated with the potential effects of estrogen on the pathogenesis of gastric CFTs. Thus, any effects of estrogen on this tumor are likely to be mediated by an alternative pathway. GPER is a membrane-associated estrogen receptor that can mediate both the rapid estrogen and traditional genomic estrogen response signal pathways ([@b36-etm-0-0-6892]). A previous study demonstrated that estrogen exerts its physiological effects through GPER in normal stromal cells ([@b37-etm-0-0-6892]). Furthermore, the activation of GPER signaling by estrogen has been reported to stimulate the formation of fibers in fibroblasts ([@b38-etm-0-0-6892]). Therefore, it can be hypothesized that the activation of GPER by estrogen may promote the formation of fibers, and even fibrosis, in the stomach. However, more basic research regarding the effects of estrogen in gastric CFTs will be required in the future to confirm this hypothesis.

Gastric CFT is a benign lesion with a good prognosis that demonstrates a predilection for female patients, especially premenopausal women. Estrogen mediated by GPER rather than ER may serve a role in this female predominance. The association between gastric CFTs and HP or HBV infection remains to be elucidated in high-calibrated studies.
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![Microscopic features of gastric calcifying fibrous tumor. (A) The mass was well-circumscribed and located in the lamina propria (H&E staining; original magnification, ×40). (B and C) Lymphoplasmacytic inflammatory infiltrate was present throughout the tumor and focally formed lymphoid follicles (H&E staining; B, original magnification, ×200; C, original magnification, ×100). (D) Psammoma and dystrophic bodies are visible in this case (H&E staining; original magnification, ×100). H&E, hematoxylin and eosin.](etm-16-06-5137-g00){#f1-etm-0-0-6892}

![Immunohistochemical features of gastric calcifying fibrous tumor (hematoxylin and eosin staining; original magnification, ×200). (A) Vimentin expression was positive; (B) estrogen receptor expression was negative; (C) G protein-coupled estrogen receptor expression was positive. (D) Immunohistochemical negative control.](etm-16-06-5137-g01){#f2-etm-0-0-6892}

![Age-sex distribution of all 48 reported gastric calcifying fibrous tumor cases. The number of female patients was twice that of male patients \<50 years of age, whereas the number was almost equal between women and men ≥50 years of age.](etm-16-06-5137-g02){#f3-etm-0-0-6892}

###### 

Clinicopathologic features of 9 cases of gastric calcifying fibrous tumor.

  Case no.   Age (years)   Sex      Smoking   Drinking   BMI (Kg/m^2^)        Concomitant disease                          Site     Layer            Size (cm)     Treatment   Complications   Follow-up (months)
  ---------- ------------- -------- --------- ---------- -------------------- -------------------------------------------- -------- ---------------- ------------- ----------- --------------- --------------------
  1          44            Female   No        No         22.89                Reflux esophagitis                           Body     Submucosa        1.5×1.0×0.8   ESD         None            25
  2          50            Female   No        No         27.06                Duodenal ulcer                               Body     Lamina propria   1.5×1.5×1.0   ESD         Celialgia       14
  3          42            Female   No        Yes        23.81                Erosive hemorrhagic gastritis hypertension   Fundus   Lamina propria   1.3×0.8×0.6   ESD         None            23
  4          61            Male     Yes       Yes        17.90                None                                         Fundus   Lamina propria   2.5×2.0×1.5   ESD         None            17
  5          46            Female   No        No         21.33                None                                         Body     Submucosa        1.7×1.5×0.2   ESD         None            11
  6          71            Male     No        No         20.24                Diabetes                                     Body     Submucosa        2.0×1.5×0.5   GWE         Celialgia       9
  7          54            Female   No        No         23.44                None                                         Body     Submucosa        2.0×1.5×1.5   ESD         None            9
  8          62            Male     Yes       Yes        27.34 (alcoholism)   Superficial gastritis                        Body     Lamina propria   2.0×1.2×0.4   ESD         None            6
  9          40            Female   No        No         19.52                Superficial gastritis                        Fundus   Submucosa        1.8×1.3×0.8   ESD         None            4

ESD, endoscopic submucosal dissection; GWE, gastric wedge excision; BMI, body mass index.

###### 

Laboratory tests of 9 cases of gastric calcifying fibrous tumor.

  Case no.   Blood routine   Tumor markers^[a](#tfn2-etm-0-0-6892){ref-type="table-fn"}^   CRP   HBV   HP
  ---------- --------------- ------------------------------------------------------------- ----- ----- ----
  1          --              --                                                            ↑     \+    \+
  2          --              --                                                            ↑     \+    N
  3          --              --                                                            ↑     N     \+
  4          --              --                                                            --    N     N
  5          --              --                                                            --    N     N
  6          --              --                                                            --    N     N
  7          --              --                                                            ↑     N     N
  8          --              --                                                            ↑     N     \+
  9          --              --                                                            --    N     N

Tumor markers consist of carbohydrate antigen 125, carbohydrate antigen 19-9, α-fetoprotein and carcinoembryonic antigen. CRP, C-reactive protein; HBV, hepatitis B virus; HP, *H. pylori*; -, in normal range; ↑, beyond normal range; +, positive result; N, negative result.

###### 

Clinicopathologic features of 39 cases of gastric calcifying fibrous tumor from previous studies.

  Author               Case no.   Country       Age (years)   Sex      Site          Layer                Size (cm)     Treatment                              (Refs.)
  -------------------- ---------- ------------- ------------- -------- ------------- -------------------- ------------- -------------------------------------- -----------------------
  Tanaka *et al*       10         Japan         43            Female   NA            Submucosa            NA            Local excision                         ([@b7-etm-0-0-6892])
  Liu and Song         11         China         32            Male     Body          Submucosa            3.0×2.0×2.0   Local excision                         ([@b8-etm-0-0-6892])
  Nascimento *et al*   12         USA           64            Male     NA            NA                   1.1           Local excision                         ([@b9-etm-0-0-6892])
  Nascimento *et al*   13         USA           65            Female   NA            NA                   0.8           Local excision                         ([@b9-etm-0-0-6892])
  Kitamura *et al*     14         Japan         44            Female   Body          Submucosa            3×2.6×2.4     LWGR                                   ([@b10-etm-0-0-6892])
  Yun *et al*          15         Korea         59            Male     Fundus        Lamina propria       3.9×2.7       LWGR                                   ([@b11-etm-0-0-6892])
  Agaimy *et al*       16         Germany       51            Male     Body          Lamina propria       2.0           Local excision                         ([@b12-etm-0-0-6892])
  Agaimy *et al*       17         Germany       77            Female   Body          Lamina propria       1.0           Local excision                         ([@b12-etm-0-0-6892])
  Agaimy *et al*       18         Germany       59            Female   Body          Lamina propria       3.0           Local excision                         ([@b12-etm-0-0-6892])
  Agaimy *et al*       19         Germany       53            Male     Antrum        Muscularis mucosae   2.0           Local excision                         ([@b12-etm-0-0-6892])
  Agaimy *et al*       20         Germany       40            Male     Body          Lamina propria       2.0           Local excision                         ([@b12-etm-0-0-6892])
  Agaimy *et al*       21         Germany       42            Female   Body          Lamina propria       3.0           Local excision                         ([@b12-etm-0-0-6892])
  Agaimy *et al*       22         Germany       51            Male     Body          Lamina propria       2.2           Local excision                         ([@b12-etm-0-0-6892])
  Pezhouh *et al*      23         USA           70            Female   NA            Submucosa            1.3           NA                                     ([@b13-etm-0-0-6892])
  Pezhouh *et al*      24         USA           39            Male     NA            Submucosa            1.5           NA                                     ([@b13-etm-0-0-6892])
  Pezhouh *et al*      25         USA           51            Female   NA            Serosa               0.5           NA                                     ([@b13-etm-0-0-6892])
  Pezhouh *et al*      26         USA           40            Female   NA            Submucosa            2.5           NA                                     ([@b13-etm-0-0-6892])
  Pezhouh *et al*      27         USA           65            Female   NA            Submucosa            1.5           NA                                     ([@b13-etm-0-0-6892])
  Shi *et al*          28         China         58            Female   Body          Lamina propria       2.3           ESD                                    ([@b14-etm-0-0-6892])
  Shi *et al*          29         China         46            Female   Body          Lamina propria       1.0           ESD                                    ([@b14-etm-0-0-6892])
  Shi *et al*          30         China         61            Male     Body          Lamina propria       2.0           EFR                                    ([@b14-etm-0-0-6892])
  Shi *et al*          31         China         53            Male     Antrum        Lamina propria       2.5           EFR                                    ([@b14-etm-0-0-6892])
  Fan *et al*          32         China         49            Male     Body          NA                   2.0×2.5       Local excision                         ([@b15-etm-0-0-6892])
  Ogasawara *et al*    33         Japan         37            Female   Body          Lamina propria       1.0           ESD                                    ([@b16-etm-0-0-6892])
  George and Abdeen    34         Kuwait        27            Female   Fundus        Submucosa            1.5×1×0.5     Surgery                                ([@b17-etm-0-0-6892])
  Zhang *et al*        35         China         55            Female   Body          Submucosa            2.0           ESD                                    ([@b18-etm-0-0-6892])
  Vasilakaki *et al*   36         Greece        60            Male     Body          Lamina propria       1.0×0.8       Local excision                         ([@b19-etm-0-0-6892])
  Attila *et al*       37         Canada        47            Female   Body          Mucosa               2.0×2.0       LWGR                                   ([@b20-etm-0-0-6892])
  Elpek *et al*        38         Turkey        25            Man      Body          Submucosa            1×0.9×0.5     Urgent surgery                         ([@b21-etm-0-0-6892])
  Puccio *et al*       39         Italy         49            Female   Body          NA                   NA            LWGR                                   ([@b22-etm-0-0-6892])
  Štofíková *et al*    40         Slovakia      68            Female   Body          Submucosa            3.2           Local excision                         ([@b23-etm-0-0-6892])
  Abbadessa *et al*    41         USA           17            Male     NA            NA                   NA            LWGR                                   ([@b24-etm-0-0-6892])
  Lee *et al*          42         Korea         49            Man      Body          Submucosa            3.0           Laparoscopic and endoscopic excision   ([@b25-etm-0-0-6892])
  Liu *et al*          43         China         37            Female   NA            NA                   NA            Endoscopic resection                   ([@b26-etm-0-0-6892])
  Lee *et al*          44         Korea           5           Female   Fundus/body   NA                   4.0×3.0       Total excision                         ([@b27-etm-0-0-6892])
  Delbecque *et al*    45         Switzerland   63            Male     Body          Submucosa            2×1.5×1.5     Local excision                         ([@b28-etm-0-0-6892])
  Azam *et al*         46         Pakistan      13            Male     Fundus        NA                   8.0×6.0×6.0   Surgery                                ([@b29-etm-0-0-6892])
  Chatelain *et al*    47         France        50            Female   Body          NA                   2.0           Local excision                         ([@b30-etm-0-0-6892])
  Jang *et al*         48         Korea         43            Female   Body          Submucosa            3.0×2.0       LGWR                                   ([@b31-etm-0-0-6892])

LWGR, laparoscopic gastric wedge resection; ESD, endoscopic submucosal dissection; EFR, endoscopic full thickness resection; NA, not available.
